Drugs / Kukoamine B Mesilate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02219971 | Aug 2014 → May 2015 | — | Tianjin Chasesun Pharmaceutical Co., LTD | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04803955 | May 2021 → May 2024 | infectious disease with sepsis | Tianjin Chasesun Pharmaceutical Co., LTD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kukoamine B Mesilate | “Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients” NCT04803955 ↗ |
| Known as | Kukoamine B mesylate | “INTRODUCTION: Kukoamine B mesylate (KB) is a mesylate chrysamine B targeting lipopolysaccharides and CpG DNA, two potential treatment targets in sepsis.” PMID 38291280 ↗ Jan 2024 |
| Route | Intravenous | “single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.” NCT02219971 ↗ |